EGFR Targeted Therapy: View from Biological Standpoint
نویسندگان
چکیده
منابع مشابه
EGFR-TARGETEd THERAPy ANd RESISTANCE
The management of non-small cell lung cancer is undergoing a paradigm shift from empirically-selected treatment to personalised therapy, based on the clinical characteristics of patients and the histological and molecular features of their tumours. This has been driven by the identification of oncogenic ‘drivers’ responsible for cancer cell growth and survival, and the development of specific t...
متن کاملEGFR blockade prevents glioma escape from BRAFV600E targeted therapy
Mutational activation of BRAF(BRAF(V600E)) occurs in pediatric glioma and drives aberrant MAPK signaling independently of upstream cues. Targeted monotherapy against BRAF(V600E) displays efficacy in pre-clinical models of glioma, however xenograft tumors adapt rapidly and escape from the growth-inhibitory effects of BRAF-targeted therapy. Here, we show that intrinsic resistance to a BRAF(V600E)...
متن کاملThe Irrational: A View from the Standpoint of Noospherology
An attempt to give a rationalistic interpretation of certain phenomena that previously belonged to the sphere of non-scientific knowledge, including the phenomena of prophecy and magic, was made. It is shown that this kind of phenomena, in principle, can occur and can be given natural-scientific rationale, if we take into account the existence of level of information processing that may be call...
متن کاملA view on EGFR-targeted therapies from the oncogene-addiction perspective
Tumor cell growth and survival can often be impaired by inactivating a single oncogen- a phenomenon that has been called as "oncogene addiction." It is in such scenarios that molecular targeted therapies may succeed. among known oncogenes, the epidermal growth factor receptor (EGFR) has become the target of different cancer therapies. So far, however, the clinical benefit from EGFR-targeted the...
متن کاملEGFR targeted therapy in lung cancer; an evolving story
Specific oncogenes with driver mutations, such as the Epidermal Growth Factor Receptor (EGFR 1) gene can lead to non-small-cell lung cancer formation. Identification of these oncogenes, their driver mutations and downstream effects allow the targeting of these pathways by drugs. Such personalised therapy has become an important strategy in combating lung cancer and highlights the need to test f...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cell Cycle
سال: 2006
ISSN: 1538-4101,1551-4005
DOI: 10.4161/cc.5.18.3277